How Australian scientists are reshaping what we know about coeliac disease, and what it means for patients, families, and the future of diagnosis and treatment.
Understanding Coeliac Disease: A Brief History
Coeliac disease is one of the most common autoimmune conditions in the world, affecting approximately 1 in 70 Australians, yet up to 80% remain undiagnosed. Globally, it's estimated to affect around 1% of the population, though rates vary by region and are likely underreported due to the wide spectrum of symptoms and limited access to testing.
The disease was first described in the second century AD by the Greek physician Aretaeus of Cappadocia, who wrote about a mysterious condition causing chronic diarrhoea and malnutrition, which he called the "coeliac affection" (from the Greek koiliakos, meaning "suffering in the bowels").
It wasn't until the 1940s that Dutch paediatrician Dr. Willem-Karel Dicke made the landmark discovery that wheat was the cause. During World War II, he observed that children with the condition improved dramatically when bread was scarce, and relapsed when it became available again. His findings, published in his 1950 doctoral thesis, revolutionised treatment and established the gluten-free diet as the cornerstone of coeliac management.
In 1954, British physician Dr. John Paulley confirmed through intestinal biopsy that the disease caused characteristic damage to the lining of the small intestine, the flattening of villi (tiny finger-like projections that absorb nutrients). This became the gold standard for diagnosis for decades.
The 1990s and 2000s brought major advances: the discovery of tissue transglutaminase (tTG) as the key autoantigen, the development of reliable blood tests (tTG-IgA), and growing understanding of the genetic component, specifically the HLA-DQ2 and HLA-DQ8 genes, which are present in virtually all people with coeliac disease.
Yet despite a century of research, there is still no cure. The only treatment remains a strict, lifelong gluten-free diet. That's why the current wave of Australian research is so significant.
What Happens in the Body, and Why It Matters
When someone with coeliac disease consumes gluten, a protein found in wheat, barley, and rye, their immune system mistakenly identifies it as a threat. The immune response triggers inflammation in the small intestine, damaging the villi and reducing the surface area available for nutrient absorption.
This leads to a cascade of consequences:
- Malabsorption of key nutrients including iron, calcium, folate, and fat-soluble vitamins
- Anaemia, fatigue, and bone density loss
- Neurological symptoms including brain fog, peripheral neuropathy, and in some cases, gluten ataxia
- Dermatitis herpetiformis, a blistering skin condition associated with coeliac disease
- In children: delayed growth, dental enamel defects, and behavioural changes
- Long-term risks include osteoporosis, infertility, and a small but elevated risk of certain intestinal lymphomas if the disease goes untreated
Critically, symptoms vary enormously between individuals. Some people experience classic gastrointestinal symptoms; others have no digestive symptoms at all. This variability is one of the biggest reasons diagnosis is so often delayed, on average by 6 to 10 years from symptom onset.
9 Groundbreaking Australian Studies Underway
1. How Little Gluten Can Cause a Response?
Brisbane, Australia
Current food regulations in Australia and New Zealand permit products labelled "gluten-free" to contain up to 3 parts per million (ppm) of gluten. In a clinical trial with 51 adults with coeliac disease, Brisbane researchers gave participants carefully measured doses of gluten ranging from 1 mg to 1,000 mg, then measured levels of interleukin-2 (IL-2) to gauge immune response. Measurable immune activation was detected after just 3 mg of gluten, and symptoms were not a reliable indicator of whether an immune response had occurred, meaning people may be experiencing silent damage without knowing it.
2. Immune Tolerance, The KAN-101 Trial (ACeD-it Trial)
Royal Melbourne Hospital
KAN-101 is an experimental immunotherapy designed to induce oral tolerance to gluten. Participants underwent controlled gluten challenges with rigorous monitoring including endoscopies. The trial has now concluded and results will inform the next generation of immunotherapy research for coeliac disease.
3. FB102, The FORTE Study
Royal Melbourne Hospital
The FORTE Study is currently recruiting adults with coeliac disease to test FB102, an experimental drug that aims to protect the intestinal lining from gluten damage. Participants follow a strict gluten-free diet then undergo a controlled gluten challenge to assess whether FB102 can shield the gut from damage.
4. The Hookworm Research
Australia
The hygiene hypothesis suggests that reduced exposure to parasites may be linked to the rise in autoimmune conditions. In a trial with 54 participants, hookworms did not cure coeliac disease but participants tolerated lower gluten challenges better, with fewer GI symptoms and improved quality of life. Researchers are now identifying the biological mechanisms that could one day be replicated in a drug.
5. A New Way to Diagnose Coeliac Disease
WEHI , Walter and Eliza Hall Institute
WEHI researchers are developing a potential world-first blood test based on gluten-specific T cells that could detect coeliac disease without requiring weeks of gluten consumption beforehand, a game-changer for people already following a gluten-free diet.
6. Children's Teeth Research
Australia
Dental enamel hypoplasia, characteristic defects in tooth enamel , is a lesser-known sign of coeliac disease in children. Australian researchers are investigating whether these dental signs, detectable at a routine check-up, could be used as a screening tool combined with a rapid finger-prick blood test to identify children with undiagnosed coeliac disease earlier.
7. The Spleen and Infection Risk
Australia
People with coeliac disease may have hyposplenism, reduced spleen function, increasing their risk of serious infections. Researchers are investigating how commonly this occurs, how to detect it, and whether pneumococcal vaccination strategies should be tailored specifically for people with coeliac disease.
8. Why Symptoms Persist Despite a Gluten-Free Diet
WEHI
For an estimated 7–30% of patients, symptoms and intestinal damage persist despite strict dietary adherence, known as non-responsive or refractory coeliac disease. WEHI researchers are studying the immune mechanisms involved, including ongoing inflammation, the role of the gut microbiome, and intestinal permeability, to find better support and treatment options.
9. Research Into the Gluten-Free Diet Itself
Australia
Australian researchers are also examining the gluten-free diet itself, including the safety of oats, hidden cross-contamination risks, why some people don't heal on a gluten-free diet, food labelling standards, and the nutritional quality of gluten-free products, which are often lower in fibre and higher in sugar and fat than their gluten-containing counterparts.
A Future Beyond the Gluten-Free Diet
From new diagnostic tools to potential treatments, from children's dental screening to gut microbiome research, Australia is truly leading the way. Each study brings us one step closer to a world where coeliac disease is easier to diagnose, safer to manage, and perhaps one day, treatable.
Research gives us knowledge. Knowledge gives us hope.
Disclaimer: This information is for awareness and education purposes only and is not medical advice. Please consult your GP or gastroenterologist for personal medical guidance. If you suspect you or your child may have coeliac disease, seek testing before removing gluten from your diet.
At Gluten Free On The Go, we're committed to keeping you informed, supported, and empowered. Explore our free downloads, school resources, and guides, because knowledge is the first step to a better tomorrow. 💚